# RECIST

Source: https://onco.cc/terms/recist/  
OnCo record `recist` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RECIST is the rulebook for measuring whether tumours have grown or shrunk on scans.

## Summary

RECIST, the Response Evaluation Criteria in Solid Tumors 1.1, is the rulebook trials use to decide from scans whether tumours have grown or shrunk. It sums the longest diameters of up to five target lesions and sorts patients into complete response, partial response, stable disease or progressive disease, with a new lesion always counting as progression. The iRECIST variant adjusts for pseudoprogression on immunotherapy. RECIST does not capture metabolic or ctDNA response, a gap behind ideas on clonal clearance as an endpoint and ctDNA futility gates. It depends on the CT (computed tomography) and MRI technologies, underpins Objective response rate (ORR), and features in ideas on AI-assisted central imaging reads and structured radiology reports.

## Fields

- Kind: Term
- Last checked: 2026-09-04
- Also known as: RECIST 1.1; measurable disease; new lesion; new lesions; sum of longest diameters; 30% decrease; ≥30% decrease; 20% increase; ≥20% increase; 30% reduction; RANO; mRECIST; PCWG3

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Response_evaluation_criteria_in_solid_tumors
- Wikipedia: https://en.wikipedia.org/wiki/Response_evaluation_criteria_in_solid_tumors

## Connected records

- terms: [Blinded independent central review (BICR)](https://onco.cc/terms/bicr/), [Complete response](https://onco.cc/terms/complete-response/), [Complete response (CR) and partial response (PR)](https://onco.cc/terms/complete-response-term/), [Duration of response (DoR) and disease control rate (DCR)](https://onco.cc/terms/duration-of-response-term/), [Lesion](https://onco.cc/terms/lesion/), [LI-RADS (Liver Imaging Reporting and Data System)](https://onco.cc/terms/li-rads/), [Objective response rate (ORR)](https://onco.cc/terms/orr/), [Partial response](https://onco.cc/terms/partial-response/), [Progression](https://onco.cc/terms/progression/), [Progression-free survival (PFS)](https://onco.cc/terms/pfs/), [Progressive disease and radiographic progression](https://onco.cc/terms/progressive-disease/), [Stable disease](https://onco.cc/terms/stable-disease/), [Surrogate endpoint validation: which stand-ins have earned trust](https://onco.cc/terms/surrogate-validation/)
- technologies: [CT (computed tomography)](https://onco.cc/technologies/ct/), [Imaging core labs and central review](https://onco.cc/technologies/imaging-core-labs/), [MRI](https://onco.cc/technologies/mri/), [Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)](https://onco.cc/technologies/quantitative-imaging-biomarkers/)
- key papers: [Prasad: most surrogate endpoints in cancer trials correlate poorly with survival](https://onco.cc/key-papers/paper-prasad-surrogate-endpoints-jama-im-2015/), [Therasse 2000: RECIST, the standard rules for measuring whether a tumour responds](https://onco.cc/key-papers/paper-therasse-recist-jnci-2000/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/)
- ideas: [A regulatory endpoint for drugs that block spread, not tumours](https://onco.cc/ideas/idea-bio2-antimetastatic-endpoint/), [AI-assisted central imaging reads to cut endpoint cost and variability](https://onco.cc/ideas/idea-tr1-ai-central-imaging-reads/), [Biopsy the one lesion that is growing while the others shrink](https://onco.cc/ideas/idea-bio1-outlier-lesion-biopsy/), [Kill combination arms early using circulating tumour DNA, before waiting for scans](https://onco.cc/ideas/idea-tr2-ctdna-futility-gates/), [Make clonal clearance, not tumour shrinkage, a trial endpoint](https://onco.cc/ideas/idea-bio1-clonal-clearance-endpoint/), [Publish the disagreement between trial doctors and independent reviewers for every trial](https://onco.cc/ideas/idea-tr2-bicr-discordance-public/), [Structured, coded radiology reports for cancer response instead of free text](https://onco.cc/ideas/idea-data-structured-radiology-response/), [Use a blood test at six weeks to decide whether to keep going](https://onco.cc/ideas/idea-bio2-ctdna-six-week-io-switch/), [Validate real-world progression against central imaging review](https://onco.cc/ideas/idea-data-rwpfs-validation-programme/), [Validate real-world progression endpoints so pragmatic trials can use them](https://onco.cc/ideas/idea-tr1-validate-real-world-progression-endpoints/)
- institutions: [Clinical Data Interchange Standards Consortium](https://onco.cc/institutions/cdisc/)

---
JSON: https://onco.cc/api/v1/entities/recist.json